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Abstract
BACKGROUND: Metabolites of the tryptophan–kynurenine pathway (i.e., tryptophan, 
kynurenine, kynurenic acid, quinolinic acid, 3-hydroxyanthranilic) may be associated with 
diabetes development. Using a case–cohort design nested in the Prevención con Dieta 
Mediterránea (PREDIMED) study, we studied the associations of baseline and 1-year changes of 
these metabolites with incident type 2 diabetes (T2D).
METHODS: Plasma metabolite concentrations were quantified via LC-MS for n = 641 in a 
randomly selected subcohort and 251 incident cases diagnosed during 3.8 years of median follow-
up. Weighted Cox models adjusted for age, sex, body mass index, and other T2D risk factors were 
used.
RESULTS: Baseline tryptophan was associated with higher risk of incident T2D (hazard ratio = 
1.29; 95% CI, 1.04–1.61 per SD). Positive changes in quinolinic acid from baseline to 1 year were 
associated with a higher risk of T2D (hazard ratio = 1.39; 95% CI, 1.09–1.77 per SD). Baseline 
tryptophan and kynurenic acid were directly associated with changes in homeostatic model 
assessment for insulin resistance (HOMA-IR) from baseline to 1 year. Concurrent changes in 
kynurenine, quinolinic acid, 3-hydroxyanthranilic acid, and kynurenine/tryptophan ratio were 
associated with baseline-to-1-year changes in HOMA-IR.
CONCLUSIONS: Baseline tryptophan and 1-year increases in quinolinic acid were positively 
associated with incident T2D. Baseline and 1-year changes in tryptophan metabolites predicted 
changes in HOMA-IR. Tryptophan levels may initially increase and then deplete as diabetes 
progresses in severity.
Type 2 diabetes (T2D)17 remains a global health concern (1). Recent metabolomics screens 
have identified tryptophan metabolites as potential biological mediators in the development 
of T2D (2–5). The majority of free tryptophan in humans is metabolized through the 
tryptophan–kynurenine pathway (6), producing one equivalent of nicotinamide adenine 
dinucleotide for each equivalent of tryptophan. Intermediates in this pathway include 
kynurenine, kynurenic acid, quinolinic acid, and 3-hydroxyanthranilic acid. The conversion 
17Nonstandard abbreviations: T2D, type 2 diabetes; IDO, indoleamine 2,3-dioxygenase; P5P, pyridoxal-5-phosphate; PREDIMED, 
Prevención con Dieta Mediterrànea; HOMAIR, homeostatic model assessment of insulin resistance; MedDiet, Mediterranean Diet; 
EVOO, extra virgin olive oil; Kyn, kynurenine; Trp, tryptophan; MD, mean difference; 3-HAA, 3-hydroxyanthranilic acid.
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of tryptophan to kynurenine is catalyzed by the rate-limiting enzymes indoleamine 2, 3-
dioxygenase 1 (IDO1), indoleamine 2, 3-dioxygenase 2 (IDO2), and tryptophan 2, 3-
dioxygenase, which are upregulated in T2D patients (7, 8). IDO1 activity may be increased 
by proinflammatory cytokines, such as interferon; this increase shifts the equilibrium of this 
pathway downstream away from tryptophan (9, 10). Further downstream conversion of 
kynurenine to 3-hydroxyanthranilic acid is catalyzed by enzymes dependent on pyridoxal-5-
phosphate (P5P) as a cofactor (11), which is deficient in diabetogenic states (12).
Studies of tryptophan metabolism and T2D in human populations are sparse. Cross-sectional 
studies have identified increased plasma concentrations of kynurenine, 5-hydroxyanthranilic 
acid, and kynurenic acid in diabetics and insulin-resistant individuals (4, 13) and lower 
concentrations of tryptophan in nondiabetics (4). The ratio of plasma kynurenine to 
tryptophan has also been reported to be directly correlated with insulin resistance (14) and 
T2D (15).These results suggest that tryptophan metabolites may play an important role in 
T2D pathogenesis.
The current study employs a case–cohort design of participants free of diabetes at baseline, 
nested within the Prevención con Dieta Mediterránea (PREDIMED) trial. In a previous 
report (16), we reported that 1-year changes in tryptophan strongly predicted lower risk of 
incident myocardial infarction and composite cardiovascular disease. Thus, we hypothesized 
that plasma tryptophan would be inversely associated with T2D. Our primary objectives 
were to address (a) whether baseline and 1-year changes in plasma tryptophan metabolites 
(tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxyanthranilic acid) were 
associated with T2D development; (b) whether baseline concentrations of these metabolites 
were associated with 1-year changes in homeostatic model assessment for insulin resistance 
(HOMA-IR); and (c) whether a Mediterranean Diet (MedDiet) intervention could offset the 
harmful consequences of an unfavorable metabolite profile.
Methods
STUDY DESIGN AND POPULATION
The PREDIMED is a primary prevention, large multicenter trial based in Spain 
(www.predimed.es). The methods of the PREDIMED trial are reported elsewhere (17). 
Briefly, 7447 participants who were free of cardiovascular disease but at high cardiovascular 
risk were allocated to 3 groups: (a) a MedDiet supplemented with extra virgin olive oil 
(MedDiet EVOO); (b) a MedDiet supplemented with mixed nuts (MedDiet nuts); or (c) a 
control diet in which participants were advised to reduce total fat intake. No calorie 
restriction or physical activity was advised. Participants were selected to the PREDIMED 
trial on the basis of either prevalent T2D or 3 or more major cardiovascular risk factors 
(smoking, hypertension, increased low-density lipoprotein cholesterol, decreased high-
density lipoprotein cholesterol, overweight or obesity, or a family history of premature 
coronary heart disease).
Within the PREDIMED cohort, 3541 participants did not have T2D at baseline. Among 
nondiabetics at baseline, individuals allocated to the 2 MedDiet groups had a 30% 
significantly lower risk of T2D than those in the control group (18). The present case–cohort 
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study sample consisted of a random subcohort of 694 nondiabetic participants selected at 
baseline (approximately 20%) from all T2D-free individuals of the PREDIMED cohort who 
had available plasma samples and all incident cases (n = 251) of T2D during a median 
follow-up period of 3.8 years with available samples (samples were unavailable for 22 out of 
the 273 incident T2D cases occurring in PREDIMED). Institutional Review Boards at each 
recruitment center approved the study protocol, and participants provided written informed 
consent.
COVARIATE ASSESSMENT
At baseline and yearly follow-up visits, a questionnaire about lifestyle variables (i.e., diet, 
physical activity, smoking), history of illnesses, medication use, and family history of 
disease was given. Physical activity was assessed with the validated Spanish version of the 
Minnesota Leisure-Time Physical Activity questionnaire (19). Participants were considered 
to have hypercholesterolemia or hypertension if a physician had previously diagnosed them 
with the condition and/or they were being treated with cholesterol-lowering or 
antihypertensive agents, respectively. Trained personnel ascertained anthropometric and 
blood pressure measurements.
BLOOD SPECIMENS AND METABOLITE PROFILING
Fasting blood samples were collected at baseline, 1 year, and biennial intervals thereafter. 
Plasma samples among diabetes-free patients at baseline (many of whom would develop 
incident diabetes later on) were collected to preserve the prospective nature of the study. 
After an overnight fast, plasma EDTA tubes were collected, and, after centrifugation, 
aliquots were frozen at 80°. In June 2015, pairs of samples (baseline and first-year visits 
from each participant) were randomly shipped on dry ice to the Broad Institute for 
metabolomics analyses.
Tryptophan–kynurenicne metabolites (tryptophan, kynurenine, kynurenic acid, quinolinic 
acid, 3-hydroxyanthranilic acid) were measured by LC-MS, as previously described (20–
22). Kynurenine and quinolinic acid were measured using an LC-MS system that comprised 
an Aquity UPLC system (Waters and a 5500 QTRAP mass spectrometer, SCIEX). 
Metabolites were extracted from plasma (30 μL) with 120 μL of 80% methanol containing 
inosine-15N4, thymine-d4, and glycocholate-d4 internal standards (Cambridge Isotope 
Laboratories). The samples were centrifuged (10 min, 9000g, 4 °C), and the supernatants (10 
μL) were injected directly onto a 150- × 2.0-mm Luna NH2 column (Phenomenex). The 
column was eluted at a flow rate of 400 μL/min, with initial conditions of 10% mobile phase 
A (20 mmol/L ammonium acetate and 20 mmol/L ammonium hydroxide in water) and 90% 
mobile phase B [10 mmol/L ammonium hydroxide in 75:25 (volume:volume) acetonitrile/
methanol], followed by a10-minlinear gradient to 100% mobile phase A. Mass spectrometer 
analyses were carried out by electrospray ionization and selective multiple reaction 
monitoring scans in the negative ion mode. To create the method, declustering potentials and 
collision energies were optimized for each metabolite by infusion of reference standards 
(20). The ion spray voltage was 4.5 kV, and the source temperature was 500 °C. Data were 
processed and visually inspected for quality of peak integration with MultiQuant software 
(SCIEX). Tryptophan, kynurenic acid, and 3-hydroxyanthranilic acid were profiled with a 
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Shimadzu Nexera ×2 U-HPLC (Shimadzu Corp.) coupled to a Q Exactive hybrid quadrupole 
orbitrap mass spectrometer (Thermo Fisher Scientific). Metabolites were extracted from 
plasma (10 μL) with 90 μL of 74.9: 24.9:0.2 (volume:volume:volume) of acetonitrile: 
methanol:formic acid–containing stable isotope– labeled internal standards [valine-d8 
(Sigma-Aldrich) and phenylalanine-d8 (Cambridge Isotope Laboratories)]. The samples 
were centrifuged (10 min; 9000g; 4 °C), and supernatants (10 uL) were injected directly 
onto a 150-× 2-mm, 3-μm Atlantis HILIC column (Waters). The column was eluted 
isocratically at a flow rate of 250 μL/min with 5% mobile phase A (10 mmol ammonium 
formate/L and 0.1% formic acid in water) for 0.5 min, followed by a linear gradient to 40% 
mobile phase B (acetonitrile with 0.1% formic acid) over 10 min. Full scan mass spectra 70–
800 m/z were acquired in the positive ion and at 70000 resolution and 3-Hz data acquisition 
rate. Other mass spectrometer settings were as follows: sheath gas, 40; sweep gas, 2; spray 
voltage, 3.5 kV; capillary temperature, 350 °C; S-lens, 40; heater temperature, 300 °C; 
microscans, 1; automatic gain control target, 1E6; and maximum ion time, 250 ms. 
Metabolite identities were confirmed with authentic reference standards. Raw data were 
processed by TraceFinder 3.1 (Thermo Fisher Scientific) and Progenesis QI (Nonlinear 
Dynamics).
To enable assessment of data quality and to facilitate data standardization across the 
analytical queue and sample batches, pairs of pooled plasma reference samples were 
analyzed at intervals of approximately 20 study samples. One sample from each pair of 
pooled references served as a passive QC sample to evaluate the analytical reproducibility 
for measurement of each metabolite, while the other pooled sample was used to standardize 
data by a “nearest neighbor” approach. Standardized values were calculated with the ratio of 
the value in each sample over the nearest pooled plasma reference multiplied by the median 
value measured across the pooled references. After standardization, the CVs measured 
among 124 pooled QC samples in the negative ion mode method were 10.2% for kynurenine 
and 17.0% for quinolinic acid. Among 92 pooled QC samples measured in the positive ion 
mode method, the CVs were 2.2% for tryptophan, 11.2% for kynurenic acid, and 39.4% for 
3-hydroxyanthranilic acid.
Fasting glucose was measured with an enzymatic method to convert glucose to 6-
phosphogluconate (Advia Chemistry Systems). The intra- and interassay CVs were 1.2% 
and 1.6%, respectively. Fasting insulin concentrations were measured with an 
immunoenzymometric assay (Advia Chemistry Systems) with an intra- and inter assay 
coefficient of variation equal to 3.7% and 4.4%, respectively. Insulin resistance was 
computed by use of the HOMA-IR method (HOMA-IR = fasting insulin × fasting glucose/
405, in which insulin is in μU/mL and glucose is in mg/dL) at baseline and 1 year (23).
ASSESSMENT OF TYPE 2 DIABETES
The PREDIMED protocol originally included T2D as a secondary endpoint. The 
adjudication of new diagnoses ofincidentcasesofT2Dduringfollow-upwasperformed by the 
Clinical Endpoint Committee of the PREDIMED, an ad hoc panel of physicians (18). 
Diagnosis of T2D was considered on the basis of 2 confirmations of fasting plasma glucose 
≥126 mg/dL (7.0 mmol/L) or 2-h plasma glucose ≥200 mg/dL (11.1 mmol/L) after a 75-g 
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oral glucose load (24). Only confirmed cases were included in the statistical analyses. The 
Clinical Endpoint Committee was blinded to the intervention group and identities of the 
patients.
STATISTICAL ANALYSIS
Individual metabolite values were first normalized by a rank-based inverse normal 
transformation (25). We also considered the ratio of plasma kynurenine to tryptophan 
(Kyn/Trp ratio) by dividing raw values for each participant and then inverse normalizing the 
ratio. Quartile cutoff points of each metabolite and Kyn/Trp ratio were generated on the 
basis of the distributions of metabolites among noncases. We calculated correlations 
between each inverse normal transformed metabolite under study with Spearman ρ. 
Baseline-to-1-year changes in plasma metabolite values according to intervention group 
were calculated by generalized estimating equations with adjustment for covariates and 
setting recruitment center as a random effect (by LSMEANS with PROC MIXED in SAS).
For the primary analyses, we fitted Cox regression models with the use of Barlow weights 
(i.e., inverse probability of selection weights) to account for the oversampling of cases and 
implemented a sandwich variance estimator to correct for correlated risk sets (26). We 
calculated hazard ratios and their 95% CI in relation to T2D for each metabolite specified as 
both categorical (quartiles) and continuous (per standard deviation) variables. Follow-up 
time was defined as the date of enrollment to the date of diagnosis of T2D for cases and to 
the date of the last visit or the end of the follow-up period for noncases (December 1, 2010). 
All models were stratified by recruitment center. In Model 1, we adjusted for age (years), 
sex (male or female), and intervention group (control, MedDiet + EVOO, MedDiet + nuts). 
In Model 2, we additionally adjusted for smoking status (never, current, or former), body 
mass index (kg/m2), leisure-time physical activity (metabolic equivalent task, min/day), 
hypertension (yes or no) dyslipidemia (yes or no), and baseline plasma glucose (with a 
quadratic term to account for nonlinearity). We conducted a test for linearity by examining 
an ordinal score based on the median value in each quartile of the metabolites. Two-sided P 
values were reported according to an α level = 0.05 after adjustment for 6 tests by the False 
Discovery Rate method (27).
We further examined the associations between 1-year changes in individual metabolites and 
Kyn/Trp ratio and risk of T2D. We first calculated the difference between baseline and 1-
year values and then normalized this difference with the inverse normal transformation. For 
this analysis, we excluded individuals with <1 year of follow-up, T2D cases diagnosed 
during the first year of follow-up, or without available samples at 1 year. All change 
analyses were adjusted by the respective baseline metabolite values. We also tested potential 
effect modification by age (<65, ≥65 years), sex (male or female), intervention group 
(control, MedDiet combined for additional power), body mass index (<30, ≥30 kg/m2), 
smoking (never, former, or current), hypertension (yes or no), dyslipidemia (yes or no) on 
the relationship between baseline tryptophan and T2D.Likelihood ratio tests were used to 
assess the significance of interactions between the stratifying variables and baseline 
tryptophan by use of the difference in number of variables as the appropriate degrees of 
freedom to report the P for interaction (Pint). Finally, we examined the association between 
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baseline metabolites and 1-year changes of HOMA-IR by using generalized linear models 
accounting for within recruitment center clustering and adjusting for covariates. Results 
were reported as the least squares mean differences (MD) (LSMEANS statement in SAS). 
All statistical analyses were performed with SAS version 9.4 (SAS Institute Inc.).
Results
The final study sample consisted of a random subcohort of 694 nondiabetic participants and 
251 incident cases of T2D occurring through a median of 3.8 years of intervention with 
available samples. Of the 892 unique participants, 641 were included in the subcohort; 53 of 
the subcohort developed T2D and 198 were incident T2D cases not in the subcohort, for a 
total of 251 cases. In addition, 663 participants (505 noncases and 157 cases) had samples at 
1 year and were included in the 1-year change analyses. Baseline descriptive characteristics 
of the subcohort according to quartiles of plasma tryptophan are shown in Table 1. Higher 
concentrations of baseline plasma tryptophan were associated with younger age, male sex, 
lower prevalence of dyslipidemia, and lower proportion of never-smokers.
Fig. 1 in the Data Supplement that accompanies the online version of this article at http://
www.clinchem.org/content/vol64/issue8 depicts the correlation matrix of the metabolites 
under study at baseline. Quinolinic acid was correlated with kynurenine (r = 0.58), while 
quinolinic acid was not correlated with tryptophan (r = −0.04). In general, all other 
correlations were moderate (Spearman ρ ranging from 0.10 to 0.33) and significant (P < 
0.05). Fig. 1 shows adjusted mean 1-year changes in the metabolites under study by 
intervention group. Individuals allocated to each of the 2 active intervention arms largely 
experienced decreases in these plasma metabolites, whereas individuals allocated to the 
control arm experienced increases in all these plasma metabolites except tryptophan.
BASELINE AND 1-YEAR CHANGES IN TRYPTOPHAN METABOLITES AND TYPE 2 
DIABETES
Table 2 displays results for the analysis of baseline tryptophan metabolites with incident 
T2D. In fully adjusted models, baseline tryptophan was prospectively associated with a 
slightly higher risk of T2D (P trend = 0.045). Associations of changes in metabolites from 
baseline to 1 year with T2D incidence are shown in Table 3. After adjusting for potential 
confounders and multiple testing, continuous 1-year changes in quinolinic acid (hazard ratio 
per SD = 1.39; 95% CI, 1.09–1.77; P 0.047) showed a positive association with T2D 
incidence.
Table 4 shows the associations between baseline metabolitelevelsand1-
yearchangesinHOMA-IR.Baseline tryptophan (MD per SD = 0.67; 95% CI, 0.46–0.88) and 
kynurenic acid (MD per SD = 0.35; 95% CI, 0.23– 0.47) were directly associated with 
changes in HOMA-IR in fully adjusted models. The baseline Kyn/Trp ratio was inversely 
associated with HOMA-IR (MD per SD = −0.18; 95% CI, −0.34 to 0.03). Table 5 shows the 
associations between 1-year changes in metabolites and 1-year changes in HOMA-IR. In 
fully adjusted models, positive changes in kynurenine (MD per SD = 0.39, 95% CI = 0.17–
0.60), quinolinic acid (MD per SD = 0.49; 95% CI, 0.18–0.80), 3-HAA (MD per SD = 0.23; 
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95% CI, 0.17–0.30), and Kyn/Trp ratio (MD per SD = 0.23; 95% CI, 0.16–0.31) were 
associated with increases in HOMA-IR by year 1.
EFFECT MODIFICATION BY DIETARY INTERVENTION AND OTHER VARIABLES
We tested whether a Mediterranean dietary intervention could potentially offset the positive 
associations of tryptophan with T2D (see Table 1 in the online Data Supplement). Using 
baseline tryptophan as the primary exposure, we observed no significant effect modification 
by dietary intervention, sex, age, obesity status, smoking status, baseline hypertension, or 
baseline dyslipidemia (see Table 2 in the online Data Supplement).
Discussion
In the present case–cohort study, we report that baseline tryptophan and 1-year increase in 
quinolinic acid were prospectively associated with higher T2D risk. Baseline tryptophan and 
kynurenic acid additionally predicted significant increases in HOMA-IR after 1 year, while 
concurrent positive changes in kynurenine, quinolinic acid, 3-HAA, and Kyn/Trp ratio 
predicted increases in HOMA-IR. Furthermore, we report no significant effect modification 
by intervention group on the relationship between baseline tryptophan and T2D. 
Interestingly, in both active intervention groups, but not in the control group, with 
Mediterranean-type diets we found reduced levels of most metabolites.
Our study adds to the growing body of literature on the tryptophan–kynurenine pathway in 
T2D pathophysiology. Previous metabolite profiling studies with T2D exist, but to our 
knowledge, the present study is the first to prospectively examine metabolites in the 
tryptophan–kynurenine pathway with T2D in the context of a dietary trial. Because 
tryptophan cannot be synthesized in humans, dietary tryptophan intake is the primary 
determinant of tryptophan availability (28). Wang et al. previously reported in a large 
prospective study of 2422 normoglycemic individuals that baseline plasma tryptophan 
concentrations were positively associated with later incident T2D (5). In a cross-sectional 
analysis of 213 participants, Chen et al. similarly reported that serum tryptophan 
concentrations were significantly increased in diabetics compared with nondiabetic controls 
(2). In another case–control study of 40 participants, tryptophan was found to be 
metabolized more quickly, and concentrations of kynurenic acid and 3-HAA were increased 
in T2D patients (4). While we confirm findings by Wang et al. and Chen et al. for increased 
tryptophan levels in T2D patients, we did not find significant associations for any other 
baseline metabolite with incident T2D. Differences between results from previous studies 
and our study may be explained by both the study design (i.e., cross-sectional vs 
prospective) and subsequent definition of case status (i.e., prevalent vs incident cases), 
wherein longitudinal studies tended to report positive associations of tryptophan with T2D 
whereas cross-sectional studies tended to report null or inverse associations. The positive 
association between tryptophan and T2D became highly significant after adjusting for 
baseline glucose, possibly owing to mediating effect of glycemic level. Our initial 
hypothesis that plasma tryptophan concentrations would be inversely associated with T2D 
(as we had previously observed with cardiovascular disease (16)) was not supported when 
using baseline data alone. However, analyses using 1-year changes suggested a more 
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dynamic picture: there may be initial compensatory increases in tryptophan at diabetes onset 
and then later depletion as diabetes progresses in severity.
Current knowledge of the role of the tryptophan– kynurenine pathway in T2D 
pathophysiology is unsettled. IDO1, a rate-limiting enzyme for the conversion of tryptophan 
to kynurenine, is upregulated in response to inflammatory cytokines (29) and may act as a 
local compensatory mechanism to limit obesity-induced inflammation (30). Thus, in 
inflammatory states such as obesity, the tryptophan–kynurenine pathway may shift in favor 
of breakdown of tryptophan into downstream products (31, 32). This hypothesis is supported 
by our finding that the baseline Kyn/Trp ratio was positively associated with insulin 
resistance but that 1-year changes in the same ratio was inversely associated with insulin 
resistance. The resulting increases in downstream products (i.e., kynurenine, xanthurenic 
acid, 3-hydroxykynurenine) in insulin-resistant individuals have been reported in previous 
publications (33–35). Overproduction of these products in the context of an inflammatory 
milieu may shift the metabolism of 3-hydroxykynurenine in favor of excessive xanthurenic 
acid production, which has been implicated in diabetes pathology (36). P5P, the active form 
of vitamin B6, is a vital cofactor in this pathway, and disturbances in P5P balance in 
conjunction with upregulation of tryptophan metabolism have been proposed as a 
contributor to insulin resistance (9). Dysregulation of the tryptophan–kynurenine pathway 
has also been proposed as a possible explanation for the observed comorbidity of depression 
and T2D (37, 38), as alterations in this pathway may affect both serotonin balance and 
inflammatory pathways (38, 39). Our results suggest that tryptophan levels may initially be 
increased during prediabetes and then depleted in the transition into a full diabetic state. 
Furthermore, we found consistent results for both baseline quinolinic acid predicting T2D 
and changes in quinolinic acid predicting concurrent increases in HOMA-IR. In the 
Framingham Heart Study, kynurenine and quinolinic acid were both found to predict higher 
HOMA-IR (34). This may be explained by the interferon –induced activation of IDO1 
(evidence by our observed association of HOMA-IR with Kyn/Trp ratio, which is an 
indicator of IDO1 or tryptophan 2, 3-dioxygenase 2 activity (40, 41)), which leads to 
increased production of toxic quinolinic acid (42).
We did not find significant effect modification by the assigned dietary treatment group on 
the association between baseline tryptophan and subsequent T2D. Richard et al. indicate that 
dietary modification for up to 10 days can lead to 15% to 20% changes in levels of plasma 
tryptophan (28). In a previous study of tryptophan metabolites and cardiovascular disease, 
we reported effect modification by diet, with a Mediterranean dietary pattern appearing to 
offset the effects of an unfavorable tryptophan profile (16). One possible explanation is that 
nuts are a rich source of vitamin B6 (43), which may compensate for potential P5P 
depletion. In both the US and Spain, around 24% of individuals had insufficient plasma 
vitamin B6 concentrations (44, 45). Thus, we continue to support a Mediterranean dietary 
pattern characterized by high intake of fruits, vegetables, whole grains, healthy oils, nuts, 
and legumes. Lastly, our finding that the intervention arms tended to decrease tryptophan 
metabolite concentrations while the control arm increased concentrations suggests that 
changes in these metabolites may partially explain the protective effect of the interventions 
on T2D.
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Our study has several strengths and limitations. We used an efficient case - cohort design to 
study a clinical endpoint and its association with multiple plasma metabolites with repeated 
measures quantified by a validated LC-MS platform. Sampling at baseline preserved the 
prospective nature of the study and reduced the possibility of differential misclassification. 
The study power may be limited, as we did not assay blood specimens for the entire 
PREDIMED cohort, although this would be cost prohibitive. Collection of data on various 
lifestyle factors allowed us to adjust for potential confounders, but the possibility of residual 
or unmeasured confounding cannot be discounted and weakens our ability to draw causal 
conclusions. Because our study sample consisted mostly of white participants in the 
Mediterranean region, there is likely minimal confounding by ethnicity or geographical 
region. At the same time, our findings may not be generalizable to other populations with 
different characteristics. Finally, we could not study several metabolites of interest, such as 
hydroxykynurenine or xanthurenic acid, as we did not target these molecules a priori.
We conclude from the present prospective study that among a population of individuals at 
high risk of cardiovascular disease, baseline tryptophan and 1-year changes in quinolinic 
acid were both positively associated with greater risk of incident T2D. Furthermore, baseline 
tryptophan and kynurenic acid and positive 1-year changes in kynurenine, quinolinic acid, 3-
HAA, and Kyn/Trp ratio were associated with greater 1-year changes in HOMA-IR. 
Tryptophan may initially increase in early diabetes onset and then deplete as diabetes 
severity progresses.
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Least mean squares 1-year changes in plasma metabolites under study according to 
intervention group.Stratified by recruitment center. Adjusted for age (years), sex (male, 
female), body mass index (kg/m2), smoking (never, current, former), leisure-time physical 
activity (metabolic equivalent tasks in minutes/day), dyslipidemia, hypertension, and 
baseline glucose. KA, kynurenic acid; Quin, quinolinic acid
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